<DOC>
	<DOCNO>NCT01535625</DOCNO>
	<brief_summary>This study evaluate safety effectiveness Momo Cobalt Chromium stent system treatment single de novo lesion native coronary artery . The stent coat diamond-like carbon decrease risk acute late stent thrombosis , increase resistance towards corrosion significantly improve endothelialisation inhibition elution metallic ion .</brief_summary>
	<brief_title>Safety Effectiveness Coronary Momo Stent</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Patients stable angina pectoris ( Canadian Cardiovascular Society [ CCS ] I IV ) unstable angina pectoris ( Braunwald classification IBC , IIBC IIIBC ) patient document silent ischemia . 2 . Patients eligible coronary revascularization angioplasty stenting CABG ( require bailout ) . 3 . Patients de novo lesion native coronary artery &gt; 50 % &lt; 100 % stenosis . 4 . One two heart vessel disease maximum 2 lesion treat stenting . Both lesion treat study stent . 5 . Target vessel suitable implantation single stent target vessel diameter ≥ 2.5 mm lesion length &lt; 20 mm . 6 . Patients leave ventricular ejection fraction ( LVEF ) &gt; 30 % . 7 . Patients willing sign write informed consent prior participation willing compliant request followup evaluation . 1 . Patients age 18 unable give inform consent . 2 . Women child bear potential . 3 . Patients currently participate another study ( whatever subject study ) . 4 . Patients participate another investigational cardiovascular drug device study , complete primary endpoint followup period within past 30 day . 5 . Patients life expectancy le 24 month factor make clinical and/or angiographic followup difficult ( fixed address , etc. ) . 6 . Patients intend major ( per principal investigator ' medical judgment ) surgical intervention within 6 month enrolment study . 7 . Patients episode sustain ischemic chest pain exceed 15 minute duration within 24 hour prior stenting patient new ST elevation within 48 hour prior stenting . 8 . Patients contraindication emergency coronary bypass surgery . 9 . Any individual may refuse blood transfusion . 10 . Patients serum creatinine &gt; 2.0 mg/dl ( &gt; 180 µmol/l ) . 11 . Patients baseline platelet count le 100,000 platelets/mm³ . 12 . Patients intolerance contraindication acetylsalicylic acid ( aspirin ) , heparin , clopidogrel ticlopidine drug therapy . 13 . Patients contrast agent hypersensitivity adequately premedicated . 14 . Patients whose target vessel stented . 15 . Any procedure treat another coronary artery schedule within 6 month implantation study stent . Exclusion criterion related angiography 1 . Patients previous PCI segment ( i.e . restenotic lesion ) . 2 . Any previous interventional procedure ( le 6 month ) anywhere within target vessel . 3 . Target lesion locate supply arterial venous bypass graft 4 . Target lesion involves side branch ≥ 2.0 mm diameter . 5 . Ostial target lesion ( within 3.0 mm vessel origin ) . 6 . Target vessel evidence thrombus excessively tortuous make unsuitable proper stent delivery deployment . 7 . Patients total occlusion ( TIMI 0 ) . 8 . Significant ( &gt; 50 % ) stenosis proximal distal target lesion might require revascularization impede run . 9 . Target lesion require treatment device predilatation balloon prior stent placement ( include limit , directional coronary atherectomy , excimer laser , rotational atherectomy , cut balloon etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>CAD</keyword>
</DOC>